BTG Plc (BTG) - Financial and Strategic SWOT Analysis Review

September 2018 | 62 pages | ID: B389D64935DEN
GlobalData

Abstracts

BTG Plc (BTG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BTG plc (BTG) develops, manufactures and sells medicines for acute care, cancer and vascular diseases. The company develops specialty drugs including antidotes for snake envenomation and toxicity related to medicines used for heart conditions and cancer; interventional vascular products for treating patients with severe blood clots and varicose veins; and interventional cancer products for treating patients with liver tumors and emphysema. The company develops products and acquires or in-licenses from other companies. BTG markets its products either directly or through distribution agreements. The company operates along with its subsidiaries in the US, Europe and Asia. BTG is headquartered in London, England, the UK.

BTG Plc Key Recent Developments

Sep 11,2018: BTG buys vascular devices firm Novate Medical
Jun 21,2018: PERT Consortium and BTG Form Strategic Partnership
May 15,2018: BTG: Final Results For year ended 31 March 2018
Apr 04,2018: SIO and BTG Announce Recipients of Immuno-Oncology/Interventional Oncology Grant Program
Jan 23,2018: BTG Names As Anne Thorburn Non-executive Director of the Board

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

BTG Plc - Key Facts
BTG Plc - Key Employees
BTG Plc - Key Employee Biographies
BTG Plc - Major Products and Services
BTG Plc - History
BTG Plc - Company Statement
BTG Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
BTG Plc - Business Description
Business Segment: Interventional Medicine
Overview
Performance
Business Segment: Licensing
Overview
Performance
Business Segment: Pharmaceuticals
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Other Regions
Performance
Geographical Segment: USA
Performance
R&D Overview
BTG Plc - Corporate Strategy
BTG Plc - SWOT Analysis
SWOT Analysis - Overview
BTG Plc - Strengths
BTG Plc - Weaknesses
BTG Plc - Opportunities
BTG Plc - Threats
BTG Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

BTG Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
BTG Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
BTG Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 11, 2018: BTG buys vascular devices firm Novate Medical
Jun 21, 2018: PERT Consortium and BTG Form Strategic Partnership
May 15, 2018: BTG: Final Results For year ended 31 March 2018
Apr 04, 2018: SIO and BTG Announce Recipients of Immuno-Oncology/Interventional Oncology Grant Program
Nov 27, 2017: BTG Announced the Appointment of Non-executive Director
Nov 14, 2017: BTG: Directorate change - Chief Financial Officer
Nov 14, 2017: BTG: Interim Results
Sep 13, 2017: Vistogard and Voraxaze Added to Revised Guidelines for Stocking of Antidotes in US Hospitals
Aug 21, 2017: BTG and SIO Expand Immuno-Oncology / Interventional Oncology Grant Programme
Jun 16, 2017: ACCESS PTS Study Demonstrates Efficacy of EKOS® Therapy for Post-Thrombotic Syndrome

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

BTG Plc, Key Facts
BTG Plc, Key Employees
BTG Plc, Key Employee Biographies
BTG Plc, Major Products and Services
BTG Plc, History
BTG Plc, Subsidiaries
BTG Plc, Key Competitors
BTG Plc, Ratios based on current share price
BTG Plc, Annual Ratios
BTG Plc, Annual Ratios (Cont.1)
BTG Plc, Annual Ratios (Cont.2)
BTG Plc, Interim Ratios
BTG Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
BTG Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
BTG Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

BTG Plc, Performance Chart (2014 - 2018)
BTG Plc, Ratio Charts
BTG Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
BTG Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Transgene SA
Sirtex Medical Ltd
Merit Medical Systems Inc
Immupharma Plc
F. Hoffmann-La Roche Ltd
CeloNova BioSciences Inc
Baxter International Inc